
National Research Corporation Net Income | NRC
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income National Research Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.6 M | 24.8 M | 31 M | 31.8 M | 37.5 M | 37.3 M | 32.4 M | 30 M | 22.9 M | 20.5 M | 17.6 M | 18.2 M | 15.5 M | 15.1 M | 11.6 M | 11.6 M | 8.49 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 37.5 M | 8.49 M | 22.2 M |
Quarterly Net Income National Research Corporation
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.7 M | -3.3 M | 3.09 M | 1.68 M | 3.99 M | -190 K | 5.79 M | 6.56 M | 5.69 M | 6.17 M | 6.36 M | 8.86 M | 7.87 M | 7.27 M | 6.96 M | 6.64 M | 8.29 M | 8.32 M | 8.53 M | 9.63 M | 9.65 M | 8.94 M | 9.23 M | 8.21 M | 9.56 M | 7.7 M | 11.7 M | 8.78 M | 8.09 M | 7.37 M | 8.17 M | 7.8 M | 6.99 M | 7.95 M | 7.31 M | 6.52 M | 4.15 M | 5.75 M | 6.52 M | 5.72 M | 4.73 M | 4.56 M | 5.51 M | 5.93 M | 4.14 M | 4.06 M | 3.48 M | 4.1 M | 4.55 M | 4.05 M | 5.45 M | 3.77 M | 3.81 M | 3.43 M | 4.47 M | 3.7 M | 3.58 M | 3.94 M | 3.85 M | 3.13 M | 2.65 M | 2.33 M | 3.46 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.7 M | -3.3 M | 5.74 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Motus GI Holdings
MOTS
|
-12.9 M | - | -34.28 % | $ 263 K | ||
|
Biodesix
BDSX
|
-35.3 M | $ 7.55 | -9.1 % | $ 57 M | ||
|
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | ||
|
Agilent Technologies
A
|
1.3 B | $ 169.82 | -3.21 % | $ 48.2 B | ||
|
Charles River Laboratories International
CRL
|
-144 M | $ 314.38 | -4.13 % | $ 15.6 B | ||
|
Quest Diagnostics Incorporated
DGX
|
992 M | $ 257.78 | -0.4 % | $ 28.6 B | ||
|
Danaher Corporation
DHR
|
3.61 B | $ 220.3 | -3.19 % | $ 157 B | ||
|
DexCom
DXCM
|
836 M | $ 79.02 | -1.46 % | $ 30.8 B | ||
|
Anixa Biosciences
ANIX
|
-10.9 M | $ 2.44 | -6.15 % | $ 79.2 K | ||
|
Celcuity
CELC
|
-177 M | $ 53.32 | -5.31 % | $ 2.49 B | ||
|
Guardant Health
GH
|
-416 M | $ 145.9 | 0.21 % | $ 18.3 B | ||
|
BioNano Genomics
BNGO
|
-26.4 M | $ 0.82 | -7.56 % | $ 4.46 M | ||
|
Bioventus
BVS
|
22.7 M | $ 9.89 | -0.65 % | $ 659 M | ||
|
IQVIA Holdings
IQV
|
1.36 B | $ 245.67 | -1.92 % | $ 42.2 B | ||
|
Laboratory Corporation of America Holdings
LH
|
877 M | $ 367.68 | -0.44 % | $ 30.6 B | ||
|
Castle Biosciences
CSTL
|
-24.2 M | $ 32.69 | -2.14 % | $ 948 M | ||
|
Mettler-Toledo International
MTD
|
869 M | $ 1 667.59 | -2.3 % | $ 34.4 B | ||
|
Illumina
ILMN
|
850 M | $ 192.79 | -3.92 % | $ 29.9 B | ||
|
Natera
NTRA
|
-208 M | $ 273.11 | -5.8 % | $ 37.3 B | ||
|
Koninklijke Philips N.V.
PHG
|
897 M | $ 28.63 | -2.22 % | $ 27.1 B | ||
|
Fulgent Genetics
FLGT
|
-60.5 M | $ 24.03 | -3.03 % | $ 740 M | ||
|
CareDx, Inc
CDNA
|
-21.4 M | $ 69.9 | -2.81 % | $ 3.72 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M | ||
|
Biomerica
BMRA
|
-3.78 M | $ 1.09 | -0.46 % | $ 3.18 M | ||
|
Interpace Biosciences
IDXG
|
24.6 M | $ 4.4 | -4.35 % | $ 19.5 M | ||
|
Lantheus Holdings
LNTH
|
234 M | $ 102.12 | 0.01 % | $ 6.89 B | ||
|
Senseonics Holdings
SENS
|
-69.1 M | $ 8.03 | -9.88 % | $ 335 M | ||
|
Sotera Health Company
SHC
|
77.9 M | $ 15.92 | -1.82 % | $ 4.52 B | ||
|
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | ||
|
ICON Public Limited Company
ICLR
|
229 M | $ 186.79 | -1.88 % | $ 14.6 B | ||
|
Co-Diagnostics
CODX
|
-46.9 M | $ 0.13 | -22.11 % | $ 173 K | ||
|
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | ||
|
Thermo Fisher Scientific
TMO
|
6.72 B | $ 668.26 | -2.95 % | $ 252 B | ||
|
DarioHealth Corp.
DRIO
|
-41.7 M | $ 1.31 | -9.02 % | $ 5.22 M | ||
|
Myriad Genetics
MYGN
|
-366 M | $ 5.47 | -1.26 % | $ 507 M | ||
|
Precipio
PRPO
|
-363 K | $ 17.46 | -5.6 % | $ 28 M | ||
|
ENDRA Life Sciences
NDRA
|
160 K | $ 3.58 | -3.38 % | $ 4.74 M | ||
|
QIAGEN N.V.
QGEN
|
425 M | $ 49.28 | -0.72 % | $ 10.7 B | ||
|
NeoGenomics
NEO
|
-108 M | $ 14.8 | -1.95 % | $ 1.9 B | ||
|
OPKO Health
OPK
|
-226 B | $ 1.58 | -2.17 % | $ 1.19 B | ||
|
Pacific Biosciences of California
PACB
|
-546 M | $ 1.64 | -7.1 % | $ 492 M | ||
|
Neogen Corporation
NEOG
|
-7.9 M | $ 10.45 | -3.73 % | $ 2.27 B | ||
|
Personalis
PSNL
|
-81.3 M | $ 14.29 | -2.96 % | $ 1.28 B | ||
|
Quidel Corporation
QDEL
|
810 M | $ 8.31 | -6.84 % | $ 350 M | ||
|
Centogene N.V.
CNTG
|
-35.5 M | - | -6.23 % | $ 30.6 M | ||
|
Waters Corporation
WAT
|
643 M | $ 438.11 | -4.11 % | $ 26.1 B | ||
|
Neuronetics
STIM
|
-39 M | $ 1.24 | -4.44 % | $ 81.8 M | ||
|
Trinity Biotech plc
TRIB
|
-31.2 M | $ 6.24 | 13.76 % | $ 2.24 B | ||
|
Exagen
XGN
|
-20 M | $ 3.59 | -5.53 % | $ 77.4 M | ||
|
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M |